Jyothsna Visweswaraiah

Company: Seismic Therapeutic

Job title: Senior Director, Biotherapeutics, Drug Creation

Seminars:

Discovery & Development of S-4321, a Novel PD-1 FcgRIIb Dual Cell Bidirectional (DcB) Agonist Antibody 9:00 am

• Current approaches to checkpoint agonism in autoimmunity • Concept of Dual Cell Bidirectional antibodies • Discovery and development of S-4321, a novel PD-1 FcgRIIb dual cell bidirectional (DcB) agonist antibodyRead more

day: Conference Day Two